Turn £10k Into £18.5k With GlaxoSmithKline plc

Even during a troubled decade, GlaxoSmithKline plc (LON: GSK) shares have performed reasonably.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskI took a look recently at AstraZeneca, and was impressed to see an overall trebling in value over the past 10 years if all dividends were reinvested.

The FTSE 100‘s other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn’t been doing quite so well — for one thing, it hasn’t had its shares boosted by takeover fever.

A 20% gain?

If you’d invested £10,000 in GlaxoSmithKline shares 10 years ago, you’d have been paying around 1,191p apiece — and at that price you could have bagged 839 shares (ignoring dealing costs).

Now, the share price has only gained 21.5% over the period, and your ten grand would have grown to £12,149. While that might have matched cash in a savings account, we really expect better from investing in shares.

But that doesn’t include dividends, so what would those have added?

Rising dividends

GlaxoSmithKline has actually been paying pretty decent dividends, starting the period offering yields of around 3.5%. But that started ramping up in 2007 as the share price fell a little, reaching 5% by 2009 — and yields have remained close to that level since. 

One thing that does mean is that dividends alone would have easily been enough to beat cash sitting in the bank, without any share price gain!

Earnings per share (EPS) can be a little volatile, but even when EPS didn’t cover the dividend in 2010, Glaxo maintained the cash payment from its own resources — and EPS was back up to normal the next year.

Another five grand!

In total, GlaxoSmithKline would have paid you an extra £4,971 in dividends, taking your total to £17,120 — and a 71% rise is starting to look reasonable.

But what if, instead of taking and spending your cash handout each year, you had reinvested it in more Glaxo shares?

Before we look at that, let me mention a thing called pound cost averaging — it’s a fancy term that just means you’ll get more shares for the same money over a period when the price dips and recovers than if it had remained flat.

For Glaxo, what that means is that you’d have added just 24 new shares at the end of 2004 when the price was around 1,440p, but by 2007 when it had dropped to 1,210p you’d have scooped up 40 of them.

A decent result

Anyway, with dividends reinvested, you’d be ending the decade with £18,594 — and an 85.5% gain is really nothing to be sniffed at, especially for a share that has actually lagged the FTSE a little over the period (but with better than average dividend yields).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »